THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE
THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE
IPW-5371 富马酸盐作为放射医学对策的药理学开发，用于治疗 FDA 动物规则下的迟发性辐射肺损伤
批准号：
10932585
负责人：
BARRY HART
金额：
$149.99万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
项目状态：
已结题
起止时间：
2023-07-01 至 2024-06-30
关键词：
AcuteAnimal ModelAnimalsBiological MarkersCharacteristicsCritical PathwaysDevelopmentEvaluationFumaratesHistologicLungOrganPathway interactionsPreparationRadiationRadiation exposureRadiation induced damageToxicologyTransforming Growth Factor betaanimal ruleinnovationirradiationkinase inhibitormedical countermeasuremultiorgan injurypharmacokinetics and pharmacodynamicspharmacologicradiation-induced lung injuryradiological imagingreceptorsmall molecule
中文摘要
翻译
本研究拟采用部分照射（PBI）动物模型，研究急性放射暴露（DEARE）对包括肺在内的多器官损伤的延迟效应。该提案的重点是支持FDA批准Innovation Pathways（小分子TGFβ受体-1激酶抑制剂MCM）的关键路径。根据FDA“动物规则”（AR）的指导标准。
英文摘要
This proposal, using partial body irradiation (PBI) animal models to study the delayed effects of acute radiation exposure (DEARE) on survival due to multi-organ injury, including the lungs. The proposal is focused on supporting the critical path for FDA approval of an Innovation Pathways, small molecule TGFβ Receptor-1 kinase inhibitor MCM. Under the guidance criteria of the FDA “Animal Rule” (AR).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACUTE RADIATION-INDUCED LUNG INJURY IN THE RHESUS MACAQUE AND ITS' TREATMENT BYIPW-5371, A SMALL MOLECULE INHIBITOR OF TGF# RECEPTOR-1 KINASE
-
批准号：10661478
-
项目类别：
-
资助金额：$11.38万
-
财政年份：2020
-
负责人：BARRY HART
-
依托单位：
ACUTE RADIATION-INDUCED LUNG INJURY IN THE RHESUS MACAQUE AND ITS' TREATMENT BYIPW-5371, A SMALL MOLECULE INHIBITOR OF TGF# RECEPTOR-1 KINASE
-
批准号：9915646
-
项目类别：
-
资助金额：$231.56万
-
财政年份：2019
-
负责人：BARRY HART
-
依托单位：
海外基金
